Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime/Sulbactam (2:1) in Respiratory and Urinary Infections
NCT01601093Phase 2Suspended
- Sponsor
- Xiangbei Welman Pharmaceuticals
- Start
- Nov 2011
- Primary completion
- Aug 2022
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of ceftazidime, sulbactam in respiratory tract infection (RTI), urinary tract infection (UTI), sponsored by Xiangbei Welman Pharmaceuticals. Started Nov 2011; status: suspended.
02
Drugs
ceftazidimesulbactam
03
Conditions
respiratory tract infection (RTI)urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT01601093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01601093.